Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity
Journal of the American Heart Association · 20.10.2026 · 15 (20)
DOI: 10.1161/jaha.126.051982 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 20.10.2026. Verfasst von Samuel B Governor und 9 weiteren Autor:innen. Beteiligte Einrichtung: St. John's Episcopal Hospital New York NY USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Mental Disorders. Die Arbeit nennt 47 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Adults with serious mental illness (SMI), type 2 diabetes, and obesity have elevated cardiovascular risk. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have established cardiometabolic benefits in the general population, but their effects in SMI are unclear. We evaluated whether GLP‐1RA use was associated with lower risks of incident myocardial infarction (MI), heart failure (HF), and all‐cause death.
Methods
This was a retrospective propensity score–matched cohort study of 218 043 adults with SMI, type 2 diabetes, obesity, and active antipsychotic or antidepressant medications in the TriNetX database (73 health care organizations). Outcomes were incident MI, HF, and all‐cause death at 1 and 3 years. The primary exposure was GLP‐1RA use versus nonuse; secondary analyses examined semaglutide or tirzepatide. Exploratory analyses evaluated sex, race, and sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use.
Results
GLP‐1RA use was associated with lower risks of incident MI, HF, and all‐cause death. Risk differences at 1 and 3 years were −0.007 and −0.010 for MI, −0.011 and −0.018 for HF, and −0.039 and −0.065 for death (all P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. John's Episcopal Hospital New York NY USA.
- Institute for Informatics, Data Science and Biostatistics Washington University School of Medicine St. Louis MO USA.
- School of Behavioral and Brain Sciences Ponce Health Sciences University Ponce PR USA.
- Bursky School of Public Health Washington University in St. Louis St. Louis MO USA.
- School of Dental Medicine Ponce Health Sciences University Ponce PR USA.
- Aurora Health Care Kenosha WI USA.
ORCID-Profile: Samuel B Governor, Eliut Rivera-Segarra, Lindsey M Filiatreau, Nelmit Tollinchi-Natali, Ekow Essien, Osamah Altaee, Leopoldo J Cabassa, Victor G Dávila-Román
Zitieren
APA
Governor, S. B., Dávila-García, D. M., Rivera-Segarra, E., Filiatreau, L. M., Tollinchi-Natali, N., Essien, E., Altaee, O., Otchere, P., Cabassa, L. J., & Dávila-Román, V. G. (2026). Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity. Journal of the American Heart Association, 15(20). https://doi.org/10.1161/jaha.126.051982
Vancouver
Governor SB, Dávila-García DM, Rivera-Segarra E, Filiatreau LM, Tollinchi-Natali N, Essien E, et al. Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity. Journal of the American Heart Association. 2026;15(20). doi:10.1161/jaha.126.051982
BibTeX
@article{Governor2026,
author = {Governor, Samuel B and Dávila-García, David M and Rivera-Segarra, Eliut and Filiatreau, Lindsey M and Tollinchi-Natali, Nelmit and Essien, Ekow and Altaee, Osamah and Otchere, Prince and Cabassa, Leopoldo J and Dávila-Román, Victor G},
title = {Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {20},
doi = {10.1161/jaha.126.051982}
}
EUVIMED